<DOC>
	<DOCNO>NCT01257464</DOCNO>
	<brief_summary>The purpose study determine whether dipeptidyl peptidase IV ( DPPIV ) inhibitor sitagliptin effective treatment cystic fibrosis-related diabetes ( CFRD ) . We hypothesize sitagliptin improve meal-stimulated insulin secretion .</brief_summary>
	<brief_title>Sitagliptin Cystic Fibrosis-Related Diabetes</brief_title>
	<detailed_description>To date , clinical trial conduct use DPPIV inhibitor sitagliptin cystic fibrosis-related diabetes . Cystic fibrosis-related diabetes characterize initially post-prandial hyperglycemia , normal fasting sugar . As disease progress , fast hyperglycemia develop . As sitagliptin augments post-prandial insulin release , avoid fast hypoglycemia , may alternative therapy cystic fibrosis-related diabetes individual yet require basal insulin therapy .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>19 year age old Cystic fibrosisrelated diabetes without fast hyperglycemia either untreated use preprandial repaglinide preprandial bolus insulin therapy Age 19 year Use basal insulin therapy Creatinine Clearance &lt; 50 mL/min Active cystic fibrosis exacerbation Pregnancy Women childbearing age use effective contraception Current prior use DPPIV inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>CFRD</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>cystic fibrosis-related diabetes</keyword>
	<keyword>incretins</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>GIP</keyword>
	<keyword>GLP-1</keyword>
</DOC>